Medicines Co. Stock
€76.00
Your prediction
Financial data and news for Medicines
sharewise wants to provide you with the best news and tools for Medicines, so we directly link to the best financial data sources.
Financials
News
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab
Key Points
- Interested in Scholar Rock Holding Corporation? Here are five stocks we like better.
- Scholar Rock expects an FDA decision on September 30 for apitegromab, an investigational treatment
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
Key Points
- Interested in Fulcrum Therapeutics, Inc.? Here are five stocks we like better.
- Fulcrum Therapeutics will merge with migraine biotech Slate Medicines in an all-stock transaction
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
Key Points
- Interested in RenovoRx, Inc.? Here are five stocks we like better.
- RenovoRx’s Phase III TIGeR-PaC trial is fully enrolled and had recorded 78 of 86 required events; final events are
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data
Key Points
- Interested in ACADIA Pharmaceuticals Inc.? Here are five stocks we like better.
- NUPLAZID is expanding its commercial reach: New-to-brand prescriptions rose 20% year over year, while
Milestone Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Milestone Pharmaceuticals Inc.? Here are five stocks we like better.
- CARDAMYST gained early commercial momentum after its mid-February launch, with more than 1,200
Scholar Rock Q2 Earnings Call Highlights
Key Points
- Interested in Scholar Rock Holding Corporation? Here are five stocks we like better.
- FDA decision remains on track for Sept. 30: Scholar Rock’s resubmitted application for
Praxis Precision Medicines Q2 Earnings Call Highlights
Key Points
- Interested in Praxis Precision Medicines, Inc.? Here are five stocks we like better.
- FDA reviews are progressing for ulixacaltamide and relutrigine, with no advisory committee
Ocugen Q2 Earnings Call Highlights
Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an
INmune Bio Q2 Earnings Call Highlights
Key Points
- Interested in INmune Bio, Inc.? Here are five stocks we like better.
- Regulatory and manufacturing progress: INmune Bio plans to seek conditional U.K. approval for Ebstrocel in late
Revolution Medicines Q2 Earnings Call Highlights
Key Points
- Interested in Revolution Medicines, Inc.? Here are five stocks we like better.
- Daraxonrasib moved closer to commercialization: The FDA accepted Revolution Medicines’ application for
BeOne Medicines Q2 Earnings Call Highlights
Key Points
- Interested in BeOne Medicines Ltd. - Sponsored ADR? Here are five stocks we like better.
- Strong second-quarter performance: BeOne Medicines reported revenue of $1.7 billion, up 30%
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
Key Points
- Interested in NewAmsterdam Pharma Company N.V.? Here are five stocks we like better.
- PREVAIL is the key near-term catalyst: NewAmsterdam expects to reach its interim event target by
Travere Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Travere Therapeutics, Inc.? Here are five stocks we like better.
- Record FILSPARI performance: Travere reported $169.6 million in total second-quarter revenue
Gilead Sciences Q2 Earnings Call Highlights
Key Points
- Interested in Gilead Sciences, Inc.? Here are five stocks we like better.
- Base business sales rose 10% year over year to $7.6 billion, led by HIV, oncology and liver treatments
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in ACADIA Pharmaceuticals Inc.? Here are five stocks we like better.
- Second-quarter revenue rose 17% year over year to $308 million, driven by DAYBUE sales of $125 million
Amneal Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Amneal Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amneal reported strong Q2 results, with revenue up 10% to $796 million, adjusted EBITDA up 12% to
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study
Key Points
- Interested in Teva Pharmaceutical Industries Ltd.? Here are five stocks we like better.
- Teva’s anti-IL-15 antibody showed encouraging 24-week results in a phase 1b vitiligo study
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
Key Points
- Interested in Belite Bio, Inc. Sponsored ADR? Here are five stocks we like better.
- Belite Bio says Tinlarebant has completed its Phase 3 DRAGON trial for Stargardt disease, and
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
Key Points
- Interested in BeOne Medicines Ltd. - Sponsored ADR? Here are five stocks we like better.
- BeOne Medicines used its ASCO investor update to signal a major push beyond hematology
Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter
Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger
This week, the U.K.'s healthcare regulatory body approved Eli Lilly's (NYSE: LLY) weight loss drug orforglipron, sold as Foundayo, for weight management and type 2 diabetes. Unlike Lilly's other
Why Eli Lilly Topped the Market Today
Eli Lilly (NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided
Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?
Stanley Druckenmiller isn't afraid to take risks. His boldness has paid off through the years. Druckenmiller's net worth stands at $7.8 billion. His Duquesne Family Office has roughly $3 billion in
Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock
Shares of biotechnology company Revolution Medicines (NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller's Duquesne Family Office drew attention to